Series C led by Pureos BioventuresFinancing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase IIISCHLIEREN / ZURICH, Switzerland (BUSINESS WIRE) Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced to.
The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.
/PRNewswire/ GlycoEra AG announced today the appointment of Ganesh V. Kaundinya, Ph.D. as President and Chief Executive Officer. Dr. Kaundinya has been a.
Financing round co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners with participation from LimmaTech Biologics AG GlycoEra AG announced today the close of a CHF 45 million ($49 million)